Colorectal Cancer Updates

Insight regarding updates to the management of patients with colorectal cancer who are microsatellite instability-high (MSI-H)/mismatch repair deficient, harbor a BRAF V600E rare mutation, or have a HER2-expressing tumor.

Data from the following clinical trials is discussed:

• Pembrolizumab vs chemotherapy for MSI-H/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. (Andre T, et al. ASCO 2020. LBA4)

• Encorafenib plus cetuximab +/- binimetinib for BRAF V600E metastatic colorectal cancer: BEACON CRC updated survival results (Kopetz S, et al. ASCO 2020. Abstract 4001)

• A phase 2, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (Siena S, et al. ASCO 2020. Abstract 4000)